Z-VAD-FMK

Catalog No.S7023

Z-VAD-FMK Chemical Structure

Molecular Weight(MW): 467.49

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Size Price Stock Quantity  
USD 117 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • (A) LAN5 cells were untreated (top panels) or treated with 50 µM of the caspase inhibitor Z-VAD-FMK (bottom panels). Cells were co-treated with nothing (No Rx), 1 µM GSK-J4, or 1 µM venetoclax for 48 hours and assayed for apoptosis by flow cytometry.

    Science, 2018, 10(441), doi: 10.1126/scitranslmed.aao4680. Z-VAD-FMK purchased from Selleck.

    After treatment with 1.5 g/l matrine in the presence or absence of 10 nM Baf A1 or 20 nM rapamycin or 10 lM z-VAD-FMK (zVAD) for 24 hrs, the cell viability was measured by CCK-8 assay. Results were expressed as mean±S.E.M. representing at least three independent experiments. *P < 0.05, versus matrine alone group.

    J Cell Mol Med, 2017, 21(6):1171-1181. Z-VAD-FMK purchased from Selleck.

  • Z-VAD-FMK (ZVF) reversed K562 cell apoptosis induced by imatinib (IM) and/or hUC-MSCs-Exo. **P < 0.01 versus K562 + IM group, ##P < 0.01 versus K562 + IM + hUC-MSC-Exo group.

    Cytotherapy, 2018, 20(2):181-188. Z-VAD-FMK purchased from Selleck.

    (A and B) Western blot analysis examining the effect of zVAD-fmk on the icaritin-induced apoptosis. The caspase inhibitor zVAD-fmk could significantly decrease the icaritin-induced cleaved caspase-3 expression. β-Actin protein levels indicate that an equal amount of protein was loaded into each lane.n=3. Mean±SD. bP<0.05, compared to the control group. eP<0.05, compared to the icaritin-treated group.

    Acta Pharmacol Sin 2014 35(4):531-9. Z-VAD-FMK purchased from Selleck.

  • Active caspase-3 expression analysis. SW1116 cells were treated with ZBH-1205, CPT-11 and SN38 at 25 μmol/L for 48 h, in the presence or absence of Z-VAD-FMK (50 μmol/L, 1 h ahead of time). *P= 0.0345. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). E: Cell cycle analysis. F: Apoptosis analysis. #P=0.0259. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). ALL experiments were repeated three times.

    Arch Biochem Biophys, 2016, 604:74-85.. Z-VAD-FMK purchased from Selleck.

    Effect on the RAS of CFZ, z-VAD-fmk, or CFZ + z-VAD-fmk treatments administered 5 or 12 days after C26 inoculation and control groups. Western blot analysis of ATF2 and pATF2. CP, ZP and UP were treated for 5 days; CT, ZT, UT and CC were treated for 12 days. CFZ (CP), z-VAD-fmk (ZP), CFZ + z-VAD-fmk (UP), PBS only (CC), healthy control (HC).

    Med Oncol, 2015, 32(4): 538 . Z-VAD-FMK purchased from Selleck.

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Features A key compound for apoptosis studies.
Targets
Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a NGTkUWVCeG:ydH;zbZMhSXO|YYm= M1PrZ|Ux|ryP NXXjWpFzOjSq M1jIU4lv\GmlYYTld{BiKHC{b4TlZ5RqfmViZX\m[YN1KGGpYXnud5Qh\XSxcH;zbYRm NVXaVoF4OjZzNkmwO|U>
HGL5 MWPBdI9xfG:|aYOgRZN{[Xl? NUDxXG1tPTEQvF2= NX[2U4FoOjSq M{jpOolv\GmlYYTld{BiKHC{b4TlZ5RqfmViZX\m[YN1KGGpYXnud5Qh\XSxcH;zbYRm MnTBNlYyPjlyN{W=
HepG2 MWLBdI9xfG:|aYOgRZN{[Xl? M4KwdFIx|ryP MYexbC=> MnmwZZR1\W63YYTl[EB1cGViYYDvdJRwfGmlIHnu[JVkfGmxbjDv[kBKUUlvMUFCpC=> MVuyOlE3PDd7NR?=
BEL-7402 MYjBdI9xfG:|aYOgRZN{[Xl? NYXTV4g3OjEQvF2= MnniNYg> M4DpboF1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA> MnLYNlYyPjR5OUW=
CEF NILBU2tMcW6jc3WgRZN{[Xl? NGjhOG0xNDN|LE[3MFExOM7:TR?= MonxNVVucW5? Mn\H[I94di2{ZXf1cIF1\XNiUGKg[Y57gW2nIHHjeIl3cXS7IITvJFQx97zHIHH0JFExOM7:TR?= MWmyOlExOjN|OR?=
SP2/0 NI\YW3ZCeG:ydH;zbZMhSXO|YYm= M3LwbVExOM7:TR?= NFnmUpEycA>? NGHSc|lFVVOR MXzicI9kc3NidHjlJIFxd3C2b4Ppd{Bw\iCVUEKvNEBk\Wyucx?= MoX0NlYxPzR5M{K=
HUVEC-2c M1;QXWFxd3C2b4Ppd{BCe3OjeR?= MWG1NO69VQ>? NHrBUYI3cA>? Ml7J[IVkemWjc3XkJJRp\SCxeD3MSGwucW6mdXPl[EBifXSxcHjh[5k> MnvSNlYxOjF5Mkm=
U1 MnfTRZBweHSxc3nzJGF{e2G7 NFTOe3IxNTFyMN88US=> MnSwNog> NV3kZ3pLemWmdXPld{BlenWpLXnu[JVk\WRiYYDvdJRwe2m|IHHu[EB{fWK|ZYH1[Y51KEiLVj2xJJJmeGyrY3H0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MUOyOVk5ODl2Mh?=
ACH-2 MULBdI9xfG:|aYOgRZN{[Xl? M2nac|AuOjByzszN MXyybC=> NYDsXIVYemWmdXPld{BlenWpLXnu[JVk\WRiYYDvdJRwe2m|IHHu[EB{fWK|ZYH1[Y51KEiLVj2xJJJmeGyrY3H0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1LNRVI2QThyOUSy
U1 MYnLbY5ie2ViQYPzZZk> MXKxNFDPxE1? M3m5T|Jp NHLqcpZqdmirYnn0d{Bk[XOyYYPlMVM> M{HlXlI2QThyOUSy
A549/V16 MVLBdI9xfG:|aYOgRZN{[Xl? MnfCOVDPxE1? NXfyRVlHOWh? NHjFO2Nz\XC{ZYPz[ZMhXEdxVF2tbY5lfWOnZDDhdI9xfG:|aYO= NFLM[nkzPTl2NkCzNy=>
SGN MoHLRZBweHSxc3nzJGF{e2G7 MnjHNlBuVQ>? NWTTOIQ6PDiq MknCbIF{KG6xIHnu[ox2\W6lZTDvckBCUUZuIHPhcJBicW5iZYjwdoV{e2mxbjDvdkBk\WyuIHHwc5B1d3Orcx?= NF3LU3AzPTh5NE[zNy=>
HCT116  NH;qTohCeG:ydH;zbZMhSXO|YYm= MW[1NO69VQ>? MnXkNog> MljBbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDESHZR M{nLOFI2QDZ6OEG4
DTK-SME NWnDT2FpSXCxcITvd4l{KEG|c3H5 M3PweVUx|ryP MV2ybC=> MnP4SG1UVw>? MofXdIFzfGmjbHz5JIlvcGmkaYTzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDieZBqfmGlYXnu[S=> M3TSflI2QDR|OEm3
HL-60 NFrlRZBCeG:ydH;zbZMhSXO|YYm= NW\QWpVPPTEQvF2= MlzCOFhp M{CxUZJm\HWlZYOgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhW0uLLVnJJJRz\WG2bXXueOKh MUmyOVgzPDB2Mx?=
U937 M4rPZWFxd3C2b4Ppd{BCe3OjeR?= MYm1NO69VQ>? Mn3WOFhp MVry[YR2[2W|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JHNMUS2LSTD0doVifG2nboVCpC=> NXTrS3JHOjV6MkSwOFM>
A549 NF\CcIhCeG:ydH;zbZMhSXO|YYm= M2frTFIxKM7:TR?= NGfHWYgzPGh? M4rJVZJm\HWlZYOgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhUE[FUDD0doVifG2nboS= NX3tNXVtOjV5OUSxOFk>
HeLa MYnBdI9xfG:|aYOgRZN{[Xl? NGL5NFUyOM7:TR?= NXO3[otqPDiq MlXL[IVkdGmwZYOgeIhmKHKjdHWgc4Yh[XCxcITvd4l{KGS{YX3heIlk[WyueR?= NUmyW5NVOjV5N{K1OFU>
SGC-7901 MWPBdI9xfG:|aYOgRZN{[Xl? NXnZ[5dsOjEEoN88US=> MXOxbC=> NXfNcJFzcW6qaXLpeJMhfGinIHPlcIwh\GWjdHigbY5lfWOnZDDifUBwgGGuaYDsZZRqdg>? M2fvO|I2PzZ5MEe2
MCF-7 MXXBdI9xfG:|aYOgRZN{[Xl? MWKxNO69VQ>? M1z2NFJp NHzwUlJqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JFND MWGyOVczOjFzNB?=
A549 M4fX[WFxd3C2b4Ppd{BCe3OjeR?= NFL6fYEyOCEQvF2= NVPOUYE5OjSq NE\SVldFVVOR MUTwdo9ud3SnczDIRmMufHKnYYTl[EBCPTR7IHPlcIwhe3W{dnn2ZYwhLiCjdITlcpVifGW|IITo[UBkdGWjdnXkJHBCWlBiZYjwdoV{e2mxbh?= NFXpOHAzPTZ6M{W2PC=>
U87 M3TkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTFVXpEPTEQvF2= MUGxbC=> MnvGdoVkd3[ncoOgZ4VtdCCpcn;3eIgh\nKxbTDUUXohfHKnYYTt[Y51 MWmyOVY5OTZ4OB?=
Neocortical Neuron MlrTUoV2em:2b4jpZ4l1gSCDc4PhfS=> NFLZVmgyODEQvF2= MYqxbC=> M13tV4FvfGGpb37pfoV{KEixaXHtbYRmKEFvSX7keYNm\CCQZYXyc5RwgGmlaYT5 MUeyOVY4PTByMR?=
Primary human placental cytotrophoblasts NVTWTFVZSXCxcITvd4l{KEG|c3H5 M3TJb|Mx|ryP MnjlNlRp NV\3[YhiTE2VTx?= NIHhToJz\X[ncoPld{B1cGViaX7obYJqfGmxbjDv[kAyOc7{LVjTSFIh[nlidILpZ4xwe2GwwrC= Ml3yNlU3PDJ3OUK=
MM MVLBdI9xfG:|aYOgRZN{[Xl? MnvoOVDPxE1? MYKyNI1qdg>? MkG3dIFzfGy7IHnubIljcXS|IGPIT{1qdmS3Y3XkJEBk\WyuIHTlZZRp MV[yOVU{ODB7OB?=
DLD1 MYnBdI9xfG:|aYOgRZN{[Xl? Mn;PNlDDqM7:TR?= MlXlNYg> M{HMUJBienSueTDy[ZZmenOnczDj[YxtKGGyb4D0c5NqeyClYYXz[YQh[nliV2PQNS=> NUfiZXhFOjV3MkSyOFY>
MDA-MB-231 M2r1[WN6fG:2b4jpZ4l1gSCDc4PhfS=> NGrhZpQyOM7:TR?= Mn\iNYg> MlG4ZZVodWWwdIOgZ4VtdCCmZXH0bEBi\nSncjDDTHVCKHS{ZXH0cYVvfA>? NGHSWWMzPTV{MUWwNS=>
MKN28 MWjBdI9xfG:|aYOgRZN{[Xl? M2TweFEx|ryP MlnpN|BucW5? NX\5OFE5TE2VTx?= NW\QNotqcW6qaXLpeJMhXE6ILd8xJJBtfXNiQ1jYMYlv\HWlZXSgZZBweHSxc3nz MXyyOVUyOzl4MB?=
HL-60 MVXDfZRwfG:6aXPpeJkhSXO|YYm= MWqxNFDPxE1? NXLUT2pFOWh? NV75V4hETE2VTx?= NVrTflVpyqCrbYDyc5ZmeyC4aXHibYxqfHlib3[gWGNPSXNvdILlZZRm\CClZXzsdy=> NVr3R|F{OjV3MEK5N|I>
AGS NHz3ZlFCeG:ydH;zbZMhSXO|YYm= MnvTNVDPxE1? M2fE[FFp MkG4dJJmfmWwdIOgZ5Vz[3WvaX6tbY5lfWOnZDDjcIVifmGpZTDv[kBk[XOyYYPlMVMtKC16LDDhcoQhNTlicILveIVqdnN? M1\0flI2PDl{MkG0
A549  M1nnSGFxd3C2b4Ppd{BCe3OjeR?= Mk[4NVDPxE1? M2X2cVI1cA>? NEHtOYdjdG:la4OgSG1CWy2rbnT1Z4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDhcoQh[XCxcITveIlkKGOnbHyg[IVifGh? MWWyOVQ{PDl6OR?=
INS-1 MXHBdI9xfG:|aYOgRZN{[Xl? MmDqOVDPxE1? NYr1UJRwPmh? MnSzSG1UVw>? NU\ZVotr\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGWjcnz5JIFxd3C2b4TpZ{Bk\Wyuc9Mg MmjNNlU1OzB6OUe=
Primary hepatocytes  MYjBdI9xfG:|aYOgRZN{[Xl? NW[5b4Y4PTEQvF2= NHzCRlUyQGh? MnTKbY5pcWKrdIOgZZBweHSxc3nzJI9nKGincHH0c4N6fGW|IHnu[JVk\WRiYomgRYN1KERiYX7kJHRPTi4QsR?= Mm\pNlU1ODd3M{i=
L929-A  MVPDfZRwfG:6aXPpeJkhSXO|YYm= M4PrW|IxyqEQvF2= M1KxZlI1cA>? MoXObY5pcWKrdIOgWG5H|rFvaX7keYNm\CClZXzsJIRm[XSq MkTxNlU{QTh3NEC=
L929-N M2rvVWN6fG:2b4jpZ4l1gSCDc4PhfS=> MkXhNlDDqM7:TR?= MnTFNlRp MoG4[Y5p[W6lZYOg[IVifGhidnnhJIF2fG:lcnnu[UBVVkcQsTDwdo9lfWO2aX;u NUDJWWxSOjV|OUi1OFA>
Cytotoxicity Assay NInu[5pE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmLaNlDPxE1? NVe0eJQ4PDiq M3;1VpBz\X[nboSgUWhOTC2rbnT1Z4VlKGOnbHyg[IVifGh? MmXKNlU{QTJzMU[=
COS7 MVfLbY5ie2ViQYPzZZk> MkHmNVDPxE1? M2fCZ|I1cA>? NVTucXM2cW6lcnXhd4V{KGOjc4Dhd4UhOy95IHHjeIl3cXSrZYO= MmnLNlU{QDRyMkW=
COS7 M2XzUmFxd3C2b4Ppd{BCe3OjeR?= NGHmWYsyOM7:TR?= NWXpeJE1PDiq NXrVXld2eGG{dHnhcIx6KHC{ZY\lcpRm\CCIQ{GwNU1qdmS3Y3XkJINmdGxiZHXheIg> MWSyOVM5PDB{NR?=
A375 NWPRNWVCSXCxcITvd4l{KEG|c3H5 M1\WSFMx|ryP M4m1blJp MlLkdJJmfmWwdIOgeIhmKGS{dXetbY5lfWOnZDDQRXJRKGOuZXH2ZYdm MUOyOVM4PjFzNR?=
A549 M1fWdmFxd3C2b4Ppd{BCe3OjeR?= MX[1NO69VQ>? MlqwNlRp MX3y[ZZmenOnczDybYJwe2:vZTDibY9o\W6nc3nzJIFv\CCjcH;weI9{cXNiY3H1d4VlKGK7IDDDbIlrd26pZHHu MonBNlU{PDl5OEG=
A549 M2rtU2Fxd3C2b4Ppd{BCe3OjeR?= NULScFJrOi53LUK1{txO NX\ke2l4OWh? NVHidW5v\GWlcnXhd4V{KHSqZTDwc5B2dGG2aX;uJI9nKGGyb4D0c5Rq[yClZXzsd{Bl\XCnbnSgc44h[2:wY3XueJJifGmxboO= M3\sflI2OzR{NEK3
 NBL-W-S  NI\Rc5BCeG:ydH;zbZMhSXO|YYm= NWLzRYlQPTEQvF2= MUCxbC=> MYLmeYxtgSC{ZYPjeYV{KGOnbHygeoli[mmuaYT5JIFnfGW{IFfBUnQuPjFidILlZZRu\W62 MUSyOVMzOzJ{Mh?=
Caki-1  MUjBdI9xfG:|aYOgRZN{[Xl? NFnKfVQ1OM7:TR?= MXq0PIg> MYny[YR2[2W|IITo[UBvfW2kZYKgc4YhSW6wZYjpckBXNXCxc3n0bZZmKGOnbHzz MnnENlUzPzlzOUG=
769-P M4LkfmFxd3C2b4Ppd{BCe3OjeR?= MknwOFDPxE1? MkXYOFhp NFzmcllz\WS3Y3XzJJRp\SCwdX3i[ZIhd2ZiQX7u[ZhqdiCYLYDvd4l1cX[nIHPlcIx{ MlTqNlUzPzlzOUG=
H9c2 M3TibWFxd3C2b4Ppd{BCe3OjeR?= M3LKNFUx|ryP M1fzRlFp NWnUTVlZcW6qaXLpeJMhTE:[LXnu[JVk\WRiY3HzdIF{\SB|IHHjeIl3[XSrb36gZpV1KG6xdDD0bIUhdG:|czDv[kBk\Wyucx?= M1Hoc|I2Ojh|OEG5
K562 M1jFdWFxd3C2b4Ppd{BCe3OjeR?= Mon0OVDPxE1? MojGOIg> NEjq[ZpqdmirYnn0d{BL[WNvQT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{ NHvwUoszPTJ2MU[xPS=>
L929 NFTDOWtCeG:ydH;zbZMhSXO|YYm= MUexNO69VQ>? NF;C[VY3cA>? NWfSO3h1cW6mdXPld{Bv\WO{b4D0c5NqeyC5aYToJHRPTg>? M4TLbVI2OTl3Nk[w
A549 M1fHcmFxd3C2b4Ppd{BCe3OjeR?= NUTPN2F1OTEQvF2= NFy0UYw{cA>? Mlj4doVlfWOnczDj[YxtKGGyb4D0c5NqeyClYYXz[YQh[nliUGHR M3;XdVI2OTZzNkm5
MCF-7 M2D1RmFxd3C2b4Ppd{BCe3OjeR?= MnPCNlDPxE1? Ml7JNog> MYXk[YNz\WG|ZYOgT2RTNXOrUl7BMYlv\HWlZXSgZZBweHSxc3nz MmLxNlUyQDJ{NEC=
OS NFz6U3NCeG:ydH;zbZMhSXO|YYm= MYeyNE81OM7:TR?= NEnVTmw4Omh? MX\pcohq[mm2czDPV{Bk\WyuII\pZYJqdGm2eTDy[YR2[3Srb36gZpkhSzZiY3XyZY1q\GV? M2jNZ|I2OTV{M{m5
HUVECs MWrBdI9xfG:|aYOgRZN{[Xl? MnnTNVDPxE1? M4H2OVJp MX9CpIlvcGmkaYTzJIFxd3C2b4Ppd{BidmRiZnHjbYxqfGG2ZYOgZZV1d3CqYXf5JIlvKESHTm[yMYlv\mWldHXkJGhWXkWFcx?= MofENlUyOzh5MEO=
EA.hy926 NUDsOndFSXCxcITvd4l{KEG|c3H5 MnTjNVDPxE1? MXyybC=> M{DMUeKhcW6qaXLpeJMh[XCxcITvd4l{KGGwZDDmZYNqdGm2YYTld{BifXSxcHjh[5khcW5iRFXOWlIucW6oZXP0[YQhTUFwaIm5NlY> NWXENYVuOjVzM{i3NFM>
Ebs M3fQUGFxd3C2b4Ppd{BCe3OjeR?= NGHMcFMyOC1zMEFOwG0> M3fMeFI1cA>? MUFCpG1OXFNiZ3Xu[ZJifGmxbjDyZZRmKGSnY4LlZZNm\CCjczD0bIUh[2:wY3XueJJifGmxbjDv[kB7NV[DRD7mcYshcW6lcnXhd4Vl MXqyOVE{PDhzNx?=
Jurkat NWjobJh{SXCxcITvd4l{KEG|c3H5 NGfhb5IzOM7:TR?= MX:yOIg> MoXTSG1UVw>? NELUdmVx[XK2aXHscJkhcW6qaXLpeEBk\WyuIHTlZZRpKG:oIFr1dotifCClZXzsd{BqdmS3Y3XkJIJ6KDFyMEW4MWY1KGOxbXLpcoVlKHerdHigWnBCyqB? NWDjRWd6OjVzMkC3NlM>
K562 MX7BdI9xfG:|aYOgRZN{[Xl? NUHueYozOC5zLUJOwG0> NV72cXM{OWh? M{DRXYlvcGmkaYTzJINt\WG4YXflJI9nKEiVUEmwJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1jNZVI2OTF7MUi4
IMR-32 MX\BdI9xfG:|aYOgRZN{[Xl? NVr3[oF3PDEEoN88UeKh MYKybC=> MXnk[YNz\WG|ZTDpckBieG:ydH;0bYMh[2WubIOgZ49ueGG{ZXSgeI8hXC1{IITvfIlv MljhNlUxQDR5NUW=
RPMI 8226 MmDnRZBweHSxc3nzJGF{e2G7 NILJWYQyODEQvF2= NVfGOWU{OWh? M4jTZoFtdW:|dDDjc41xdGW2ZXz5JIJtd2OtczDj[YxtKGSnYYToJINifXOnZDDifUBv\WO{b4P0ZZRqdi1z MVmyOVA{Pzh3MR?=
U266  MW\BdI9xfG:|aYOgRZN{[Xl? MoHCNVAx|ryP NXPPR3NXOWh? NIqzc4Zx[XK2aXHscJkh[myxY3vzJINmdGxiZHXheIgh[2G3c3XkJIJ6KG6nY4Lvd5RifGmwLUG= M{LQZVI2ODN5OEWx
H929  MlG0RZBweHSxc3nzJGF{e2G7 M4XqVlExOM7:TR?= NEjwTZUycA>? NFn6b|Rx[XK2aXHscJkh[myxY3vzJINmdGxiZHXheIgh[2G3c3XkJIJ6KG6nY4Lvd5RifGmwLUG= Mn;VNlUxOzd6NUG=
MM.1S  MlPZRZBweHSxc3nzJGF{e2G7 MlvYNVAx|ryP NXTOZmt[OWh? NWS0VZc3\W[oaXPp[Y51dHlicILleoVvfHNic3;yZYZmdmmkLXnu[JVk\WRiY3XscEBl\WG2aDDjc41jcW6nIIfpeIghdmWlcn;zeIF1cW5vMR?= M{PDbVI2ODN5OEWx
C6 NUjafXE1SXCxcITvd4l{KEG|c3H5 MYO1NO69VQ>? NGDCV4s1QGh? NGDsXZlxemW4ZX70d{B1cGVibH;zd{Bw\iClZXzsJJZq[WKrbHn0fUBk[XW|ZXSgZpkheHKnZ37lco9td26n NYSyWlJuOjVyMUO0O|k>
AGS NGfp[npCeG:ydH;zbZMhSXO|YYm= M3nIW|Ux|ryP NYi0Z40zOjSq MWDhZo9tcXOqczFOtk1t[XCjY3jvcoUucW6mdXPl[EBk\WyuIHTlZZRpKGGwZDDpcohq[mm2ZXSg[5Jwf3Sq MVqyOVAxQTZ7OB?=
HeLa  Mnr2RZBweHSxc3nzJGF{e2G7 NWLkVZpRPDEQvF2= M3Ty[FI1cA>? NGPZXJdqdmirYnn0d{B1cGViaX7jdoVie2WmIHHwc5B1d3OrczDpcoR2[2WmIHL5JJNqWk6IMUKx MlLFNlQ6Ojh4OEW=
THP-1  NFjHfFVCeG:ydH;zbZMhSXO|YYm= NHnCPXoyOM7:TR?= NH\LNG8ycA>? Ml3VdoVlfWOnczDhdI9xfG:|aYOgbY5lfWOnZDDifUBCVEFvU1TUxsA> MkjvNlQ6OjN4NUO=
P815  NILWXYdCeG:ydH;zbZMhSXO|YYm= MoLFNVAxKML3TR?= M1LuUlEzcA>? NYH6coNqTE2VTx?= MUTpcohq[mm2czD2bZJ2ey2rbnT1Z4VlKGGyb4D0c5Nqew>? NF\QcGUzPDl{M{K3Ny=>
HCT116 NXv6RoV2SXCxcITvd4l{KEG|c3H5 MonQNlDPxE1? NUfSSXRNOjSq M3HDXoFjem:pYYTld{Bw\iCWUT3pcoR2[2WmIHHwc5B1d3Or MVuyOFg6ODR2OR?=
SW1116  MVjBdI9xfG:|aYOgRZN{[Xl? NWG5WYRbOTBiwsXN NYfqUZYyOWh? NF\HTZdFVVOR M160WJJme3S{YXnud{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JIdm\mm2aX7pZkBxdHW|IHTlZ4l1[WKrbnW= NH:yNGkzPDh5NEK4Oi=>
LOVO Ml7lRZBweHSxc3nzJGF{e2G7 MYixNEDDvU1? M2T0[lFp M4jTS2ROW09? NUPFW|U2emW|dILhbY5{KGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkh\2WoaYTpcoljKHCudYOg[IVkcXSjYnnu[S=> NUjNWXdpOjR6N{SyPFY>
SNU449  Mk\GRZBweHSxc3nzJGF{e2G7 NIG4W|UzOM7:TR?= M3G5cFQ5cA>? M1;OOGROW09? MUfk[YNz\WG|ZYOgcYlTNTR3MT3pcoR2[2WmIHHwc5B1d3SrYx?= M3y4TVI1QDRzNkO4
Caco-2 NFeyVpZCeG:ydH;zbZMhSXO|YYm= MXK0NQKBkc7:TR?= MnTSOIg> MYPwdoV3\W62czDTWE04NWmwZIXj[YQhYk9vMTDjbIFv\2W|IHHu[EBVTVJiZILvdC=> MoPCNlQ5OjJzOEO=
macrophage MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVmwMVIxOM7:TR?= M4\vPFI1cA>? MYjpcoR2[2W|IGTOSk0h[W6mIGLpdFMu\GWyZX7k[Y51KG6nY4LvdJRwe2m|IHnuJI1i[3KxcHjh[4U> NHiyO2IzPDd7OUW2OS=>
AGS  M4r2U2Fxd3C2b4Ppd{BCe3OjeR?= MV[yNO69VQ>? M3LTU|EzcA>? MnXoSG1UVw>? NFn2PWNz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gZZBweHSxc3nzJIlvKHKnc4DvcpNmKHSxIITo[UBGfE:DYzDmdoFkfGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXvCeXc3OjR5OEm3NFM>
LCC9  M1HWcWNmdGxiVnnhZoltcXS7IFHzd4F6 MnHVNVAx|ryP MorYOYQ> NWHC[ZdE[myxY3vzJINmdGxiZHXheIghcW6mdXPl[EBjgSClb33ibY5ifGmxbjDMNVch[W6mIHPocI9zd3G3aX7l Ml\zNlQ4QDV{NU[=
U937  M4HEWI5m[3KxcITvd4l{KEG|c3H5 M33H[lExyqEQvF2= M4izSFMxyqCvaX6= NXPkVIpGcW6mdXPld{Bv\WO{b4D0c5NqeyClb33ibY5mKHerdHigWG5H NXrufmp{OjR5N{O3OVY>
T cell M3nVcGNmdGxicILvcIln\XKjdHnvckBie3OjeR?= NWjIXZBuOC1zMEFOwG0> M2C5blczcA>? NFLxd41KSzVyPUewJO69VSxiaX7obYJqfHNiYX70bU1ETDNvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjDpckBRSk2Fcx?= MU[yOFc3QDdyNx?=
HeLa  NVPYZY91SXCxcITvd4l{KEG|c3H5 NIjzdZk2OM7:TR?= MUC3Nog> MlH2SG1UVw>? MVPwdoV3\W62czDhdI9xfG:|aYOgbY5lfWOnZDDifUBkd22yb4Xu[JPDqDIkgKO1 M1nIVFI1PzV2N{i2
HeLa  NWHxWpRYSXCxcITvd4l{KEG|c3H5 NEfDZ4wyODEQvF2= NX7UR4psOjSq NX7mcYI2e3WycILld5NmeyC{YYTlJI9nKGOnbHyg[IVifGhiaX7keYNm\CCkeTDveoVz\XiycnXzd4lwdiCxZjDHOVlUKG:{IFe3NXIheDF3MHfseYVlyqB? M3r3UVI1PzJ{NE[4
IEC-6  NWfJb4ttSXCxcITvd4l{KEG|c3H5 MYmxNO69VQ>? NWfaPZBHOjSq M4\0OJBz\X[nboTzJHRk\EFvaX7keYNm\CClYYPwZZNmNTNiY3zlZZZi\2ViYX7kJO6zNWOjdHXubY4h\GWpcnHkZZRqd25? MkK4NlQ4OTF3N{G=
HCT116 MVfBdI9xfG:|aYOgRZN{[Xl? MnTBNlDPxE1? MmDxNlRp NWXSWHoycW6qaXLpeJMhfGinIHPlcIwh[XCxcITveIlkKGmwZIXj[YQh[nliWVzUNlA2 MnmxNlQ4OTN6MUK=
L02 NVfNToFXSXCxcITvd4l{KEG|c3H5 MWqyNO69VQ>? NIHp[YgycA>? MXrwdoV3\W62czD0bIUh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBOTUiS MmPlNlQ4ODZ2NkG=
A375 MULBdI9xfG:|aYOgRZN{[Xl? MnG0NlDPxE1? NUDPSnBCOjSq NV7TeGxRemW4ZYLz[ZMh\GmlaYTybY5wdmViQj3pcoR2[2WmIHHwc5B1d3Orcx?= NHrwVlkzPDZ7OUGxNS=>
HDPC NGX5N4FCeG:ydH;zbZMhSXO|YYm= NHftb3c2OML3TR?= Mn\uNlRp MXfpcohq[mm2czDOU{1qdmS3Y3XkJIFxd3C2b4Ppdy=> MX:yOFY{PDV7Mx?=
A549 NVnqV255SXCxcITvd4l{KEG|c3H5 NVS5[nR2PTEEtV2= MlGxNog> NGfTbY9FVVOR Mk\vdJJmfmWwdIOgeIhmKGi7cH;kbZBtd2mmIFTORUBkd262ZX70JJBp[XOnIHnu[JVk\WRiYomgZ4VxcGGub3Podo9ucW5? MV2yOFU5QDF|NR?=
 BV-2 Mn;jRZBweHSxc3nzJGF{e2G7 NHXDdHYzOM7:TR?= NFvhPVYzcA>? M4LZeZN2eHC{ZYPz[ZMhXVZvaX7keYNm\CClaILvcYF1cW5iZYj0dpV{cW:wIHHu[EBlcWyjdHnvckBw\iC2aHWgcpVkdGWjcjDlcpZmdG:yZR?= MVqyOFU2QDFzOB?=
HT-29  MmjJRZBweHSxc3nzJGF{e2G7 MnyyOVDPxE1? MWm0PIg> NVq1[5B3[myxY3vzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDrZYVueG[ncn;s NY\GfppMOjR3NEmxO|U>
A549 M4TXTGFxd3C2b4Ppd{BCe3OjeR?= NX;ybpNxPc7:TR?= NXHuPXBJOjSq MV;zeZBxemW|c3XzJFZmyqBqQluxNFA1OClvaX7keYNm\CCjcH;weI9{cXQEoB?= NGXESoEzPDV{OUi3NS=>
MIA-PaCa-2 NHvodXZCeG:ydH;zbZMhSXO|YYm= MnzONlRp MXnicI9kc3NiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIlv\HWlZXSgZpkh[m:2aDDBMVQ1OzZ3NDDhcoQheGGlbHn0ZZhmdA>? MmflNlQ2OTB7OUK=
Caki-1 MXfBdI9xfG:|aYOgRZN{[Xl? NWmyRXlLOjEQvF2= Mo\YNYg> NUfsfVgxcW6qaXLpeJMhW0OSLXnu[JVk\WRiYYDvdJRwe2m| Mlv0NlQ2ODR4OEG=
CLL M4W5VmFxd3C2b4Ppd{BCe3OjeR?= MlzxNlXPxE1? NYnscGNHOWh? NYeycZp7eGG{dHnhcIx6KGKub3Prd{BOVE5{MkO4MYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN? MnrKNlQ1Pjd4M{S=
SGC-7901 NV3NPYRsSXCxcITvd4l{KEG|c3H5 NES3eW4yOM7:TR?= NUXzW3dTOjSq NF7LOW9xem:vb4Tld{B1cGViQ1fJTU1qdmirYnn0[YQh[2WubDDndo94fGhiaX6gV2dENTd7MEGgZ4VtdHN? Mn7jNlQ1PTR2OEi=
k1735 NFLCdYpCeG:ydH;zbZMhSXO|YYm= M1\HeFIx6oDLzszt MnriOIg> M1zjRolvcGmkaYTzxsBU[Wyvb37lcIxiNWmwZIXj[YQh[XCxcITvd4l{ M{HZ[lI1PDVzMUG2
HaCaT  NU[zNZloSXCxcITvd4l{KEG|c3H5 NGTifVYyODEQvF2= NGq1OpAycA>? NHPUZppjdHWwdIOgWXZDNWmwZIXj[YQh[XCxcITvd4l{KGmwIFjhR4FVKGOnbHzz M3jO[FI1OzV4OUm3
podocytes MULBdI9xfG:|aYOgRZN{[Xl? MYWyNFDPxE1? MlPqOog> NGjLZYtqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSB|LEStSGdG M3KzWVI1OzN5N{e3
 KB NV;IRmFjSXCxcITvd4l{KEG|c3H5 MlHnOVDPxE1? NUfwfHF2OjSq NXG4U4JGcW6qaXLpeJMhVGmlbz3BMYlv\HWlZXSgZ4F{eGG|ZT2zJIFv\CCSQWLQJIFkfGm4YYTpc44> M1HITFI1OzN5NEmy
 HepG2  MVLBdI9xfG:|aYOgRZN{[Xl? M{OyPVEx|ryP MnuyNlRp NHPjd4pz\WS3Y3XzJJZqdWWwdHnuJINt\WG4YXflJINifXOnZDDifUBNWFN? NI\qVFQzPDN{NUixOi=>
fetal rat lung fibroblasts  NXThbHpDU2mwYYPlJGF{e2G7 MYi4NO69VcLi NUPwbHBbOWh? M4HTV4lvcGmkaYTzJGNie3Cjc3WtN{Bi[3Srdnn0feKh NYHTb4VjOjR|MUSxN|U>
PDL fibroblasts NFrseVNMcW6jc3WgRZN{[Xl? MWO4NO69VcLi NU\OVVlrOWh? MoLobY5pcWKrdIOgR4F{eGG|ZT2zJIFkfGm4aYT5xsA> MlOxNlQ{OTRzM{W=
MB49 NYDYOGloSXCxcITvd4l{KEG|c3H5 NIPjXWgzOM7:TR?= NEjhW5oycA>? NV7FO2lTemW4ZYLz[ZMhS01vaX7keYNm\CClZXzsJIRm[XSq NW\FeXJwOjR{OEK0N|M>
5637 MUPBdI9xfG:|aYOgRZN{[Xl? M{\HW|Ix|ryP MUOxbC=> Mo\qdoV3\XK|ZYOgR20ucW6mdXPl[EBk\WyuIHTlZZRp MUiyOFI5OjR|Mx?=
A549  NH\rUGxCeG:ydH;zbZMhSXO|YYm= MoDBNVAx|ryP MXm0PIg> NH:zeFJ{fXCycnXzd4V{KHSqZTDhdI9xfG:|aYOgZ4F2e2WmIHL5JJBqeGW{aX7lxsA> MWeyOFI4OjJyMR?=
MCC-2 MmnoRZBweHSxc3nzJGF{e2G7 Mo[xNlAh|ryP MUG2bC=> MkPNSG1UVw>? NIXF[2ZjdG:la4OgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6nIHHwc5B1d3OrczDj[YxtKGSnYYTo NHPLeI4zPDJ4Mk[1PC=>
ADF M3HEbmFxd3C2b4Ppd{BCe3OjeR?= MY[0NO69VQ>? NVPMSWlkPmh? NEjOb|lqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> NHO4bmgzPDJ{OEKzNi=>
 U373  M17qdmFxd3C2b4Ppd{BCe3OjeR?= M2C2XFQx|ryP NXe5VnF3Pmh? NFyzcZRqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> NHrYO|IzPDJ{OEKzNi=>
RKO-HIPK2i MoXHRZBweHSxc3nzJGF{e2G7 NHfGe2I1OM7:TR?= NUfSeW1CPmh? M4jtNYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOqZX3veIhmemGyeTDwcJV{KFqwQ3yy MkfyNlQzOjh{M{K=
HEC-1B NHHkeGJCeG:ydH;zbZMhSXO|YYm= NIDiWlUzOM7:TR?= MV6xbC=> NYHBVYx1emWmdXPld{BVWC2rbnT1Z4VlKGGyb4D0c5Nqe8LiY3HzdIF{\S1|IHHu[EBk[XOyYYPlMVk> MVGyOFIyOzN3OB?=
4T1 Mom1R4VtdCCYaXHibYxqfHliQYPzZZk> NGSzfZAzNjVvMUFOwG0> MnXsOIg> NW\kcHJ1TE2VTx?= MX\y[ZNkfWW|IITo[UBkgXSxdH;4bYNqfHlib3[gOHQyKGOnbHzzJIlv\HWlZXSgZpkhW1CGVDDpckBiKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70JI1idm6nch?= NFy0[W8zPDJyNkG2NS=>
OS  NUXCO4xySXCxcITvd4l{KEG|c3H5 NGLYfmYzOM7:TR?= NUHObmZXPGh? MXvpcohq[mm2czD0bIUh[2WubDDk[YF1cCClYYXz[YQh[nliUFTU MWOyOFIxPDl|Nx?=
RPE NWnaN45MSXCxcITvd4l{KEG|c3H5 NWPOe25pOTByzszN MUG0PIg> Mme3dIFzfGmjbHz5JIlvcGmkaYTzJJRp\SClYXzwZYlvNTFiYX7kJE0zKGGldHn2ZZRqd25iYYOge4VtdCCjczD0bIUh[2G|cHHz[UBi[3SrdnH0bY9v MWSyOFIxOjB3Mh?=
UD29a NIDJb3VCeG:ydH;zbZMhSXO|YYm= NILjdpE2OM7:TR?= MWGyOIg> MoG0bY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiY3H1d4VlKGK7IF7VWFM> NWjSe29OOjRzOUC1O|Q>
SH-SY5Y  NVnx[2l4SXCxcITvd4l{KEG|c3H5 MoD6NVDPxE1? MnrsNlRp MWTheJRmdnWjdHXzJINie3Cjc3WgZYN1cX[jdHnvckBidmRiY3XscEBl\WG2aDDpcoR2[2WmIHL5JGhPTS1{RFe= NFntV|gzPDF2NUS2Ny=>
HeLa  M1jFR2Fxd3C2b4Ppd{BCe3OjeR?= MVmxNE8zOM7:TR?= MnPLNlRp NXe1VZd7cW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJJRp\SCvYXrvdol1gSCxZjD0bIUhdWWvYnXyd{Bw\iC2aHWgZ4F{eGG|ZT3mZY1qdHl? Mlr0NlQyOzd{Nk[=
SCCVII  NWnuVXU2SXCxcITvd4l{KEG|c3H5 MmfXNlXPxE1? NE\DdnQycA>? NUn4[HlicW6qaXLpeJMhfGinIHPlcIwhc2mubHnu[{Bi\nSncjDkZZNifGmwaXK= NF;CfmYzPDF{NkS2OC=>
RAW 264.7 MVjBdI9xfG:|aYOgRZN{[Xl? NXLpZWdxOjEQvF2= M1Lud|E5cA>? M2H2eIlv[3KnYYPld{BNSzNvSVmv{tIu[WO2aX6gdoF1cW9iY3;tdIFz\WRidH:gSWNVXi2PT2OgeJJm[XSvZX70JI9vdHl? NVzpeWhDOjRzMU[3NFc>
A549  M37IRmFxd3C2b4Ppd{BCe3OjeR?= NVvMTGtQOi53zszN Ml7GNlRp M4HPOoRm[3KnYYPld{Bwemmmb37pck1qdmS3Y3XkJIF2fG:yaHHnfUBieyC5ZXzsJIFv\CCOb4PzJI9nKM7Wz5jtJIFte29ib3PjeZJz\WRiZIXybY5oKGG3dH;wbIFocWNicILvZ4V{ew>? MmSwNlQyODJ3MkK=
UM-SCC-10A  M2TjN2Fxd3C2b4Ppd{BCe3OjeR?= MV[1NOK2VQ>? NF:2dGszcA>? NXm4UGRjemWmdXPld{BieG:ydH;zbZMhcW6mdXPl[EBjgSCqaXfoMYRwe2ViaYPvZYxidnSxbHHjeI9v\Q>? NY\KVpVZOjRyOUi3OVM>
BGC-823 NYLVNphLSXCxcITvd4l{KEG|c3H5 NX\mVYZKOTBizszN NGXWVWczPGh? MkXWdoVlfWOnczD0[ZRz[W6mcnnu[U1qdmS3Y3XkJIFxd3C2b4Ppd:Kh NV;QT5NmOjRyOUi1NVE>
Nalm-6  NHPEfoFCeG:ydH;zbZMhSXO|YYm= NF3VWlIzOM7:TR?= MmfZOIg> M2fqbIlvcGmkaYTzJINie3Cjc3WtPEBidmRiY3HzdIF{\S1|IHHjeIl3[XSrb36gZY5lKFCDUmCtNUBkdGWjdnHn[S=> M3[xdVI1ODN7OU[3
KHOS  MULBdI9xfG:|aYOgRZN{[Xl? NF:yWpM1OM7:TR?= MWSyOIg> MXzicI9kc3NidHjlJIlv[3KnYYPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiaX7keYNm\CCkeTDCRm1FO8Li NYnWUnFMOjRyMkWzOlE>
G292 MVzBdI9xfG:|aYOgRZN{[Xl? NVHaelB2PDEQvF2= NEf2eHMzPGh? NXvFSoY5[myxY3vzJJRp\SCrbnPy[YF{\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIFv\CCSQWLQJIlv\HWlZXSgZpkhSkKPRERCpC=> MVGyOFAzPTN4MR?=
MG-63 MV7BdI9xfG:|aYOgRZN{[Xl? NYXERVNbPDEQvF2= MXSyOIg> NFyzNIxjdG:la4OgeIhmKGmwY4LlZZNm\CClbHXheoFo\SCxZjDjZZNx[XOnLUOgZY5lKFCDUmCgbY5lfWOnZDDifUBDSk2GM9Mg M4PsOVI1ODJ3M{[x
EBV-transformed B cells NIf2NmtCeG:ydH;zbZMhSXO|YYm= M3HkZ|Ix|ryP M2LSPVJp NGLKcpRFVVOR Mlm4Zoxw[2u|IHHueIkuS0R6MDDhcoQh[W62aT3DSFg3KGGwdHnic4R6NWmwZIXj[YQh[XCxcITvd4l{ M1PkZlI1ODB6NkK4
IM-9 B MVLBdI9xfG:|aYOgRZN{[Xl? MYWyNO69VQ>? NXXSdmRLOmh? NVrFV45DTE2VTx?= Mo[zZoxw[2u|IHHueIkuS0R6MDDhcoQh[W62aT3DSFg3KGGwdHnic4R6NWmwZIXj[YQh[XCxcITvd4l{ NEfH[YUzPDByOE[yPC=>
CNE1 NV3BOoh2SXCxcITvd4l{KEG|c3H5 MXqyNO69VQ>? NV3neVdwPDiq Ml;YZoxw[2u|IFzLMWEucW6mdXPl[EBieG:ydH;zbZM> MVeyN|k5PTB{OR?=
CNE2 NWDlPZd{SXCxcITvd4l{KEG|c3H5 NV;1eJNlOjEQvF2= M3nufFQ5cA>? MWficI9kc3NiTFutRU1qdmS3Y3XkJIFxd3C2b4Ppdy=> NVq2NXZZOjN7OEWwNlk>
HL-60 NEm3OWJCeG:ydH;zbZMhSXO|YYm= MXW1NOK2VQ>? Ml;nNYg> NXHYZnR6TE2VTx?= M{W2RYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEKDMUS1 NYjlSnNCOjN7NEi3OVE>
L929 NYPsOmZkSXCxcITvd4l{KEG|c3H5 M3TyOVEvOjYkgKO1xsDPxE4EoB?= MV:yOIg> M2PuZ4F2\22nboTzJHRPTs7zLXnu[JVk\WRibnXjdo9xfG:|aYOgZY5lKGG3dH;wbIFogQ>? M3LWVVI{QTRzN{[5
Jurkat NHvkOpZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVPBUGRmOs7:TR?= MofLOIg> Mli3doV3\XK|ZYOg[5Jwf3SqIHnubIljcXSrb36gZY5lKM7{LXPheIVvcW5iZHXjdoVie2ViYomgTHMuSVOD NHLBbJIzOzh7NkC2NS=>
RAW264.7  NWfHWm1ySXCxcITvd4l{KEG|c3H5 MlXTNVAh|ryP M1PuSFI1cA>? MoSw[IVkemWjc3XzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDHRS=> NVH6V3FnOjN6MkCyNFM>
A431  MmjJT4lv[XOnIFHzd4F6 MYS0NO69VQ>? MX[ybC=> MWDicI9kc3NiZnnz[ZRqdi2rbnT1Z4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2W|IHHu[EBRSVKS MYWyN|gxODB3OB?=
Jurkat M2HaeGNmdGxiVnnhZoltcXS7IFHzd4F6 NHHwSVAzPS1zMEFOwG0> MkfZOog> M2WydYlvcGmkaYTzJJouTkFvQ13LMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NVPLemY2OjN7M{O1N|I>
COS-7  M4\YVGZ2dmO2aX;uJGF{e2G7 NGDUbWQ2OML3TR?= M3nGeVI1cA>? Mm[0ZYZn\WO2czD0bIUheHKxY3Xzd4lv\yCxZjDBWG4yeyC5aYToJJBwdHmTIITyZYN1ew>? NE\abZkzOzl|M{KwPC=>
CAL27 NGDnbHZCeG:ydH;zbZMhSXO|YYm= MYexNEDPxE1? MVKybC=> NYPsT2Mye3WycILld5NmeyCFdYKtUnB{NXKnZIXj[YQhfmmjYnnsbZR6KGK7IIXwJJRwKDlyJR?= MUiyN|kyPzN7Nh?=
THP-1  NX73UY9VSXCxcITvd4l{KEG|c3H5 NGH0fJoyOC13MN88US=> M3HGSFJp M3HtW4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KHS{aYD0c4xq\GV? MXuyN|kxODJ7OR?=
K562 NFT1T2pCeG:ydH;zbZMhSXO|YYm= NFL1W4wzOM7:TR?= MmLROFhp M1K5T4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KDRvTWW= M2iydlI{QDd4OEK2
HL-60 MojnRZBweHSxc3nzJGF{e2G7 NFLWdIkyODEQvF2= MU[yOIg> NGPhW2tqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCjYnnleIFv\SCmaYTldpBmdmW|wrC= MWCyN|g3PTd5OB?=
HeLa  MUDBdI9xfG:|aYOgRZN{[Xl? MXiyNO69VQ>? MV2ybC=> Mk\mbY5pcWKrdIOgSG1OWCCrbnT1Z4VlKGGyb4D0c5Nqew>? NWG0eoltOjN6NkO5OlY>
U251 NEHTbmVCeG:ydH;zbZMhSXO|YYm= M1uyfVIx|ryP MYCyOIg> NVf4N2g3cW6qaXLpeJMh[2G|dHnjbY4hcW6mdXPl[EBIOi:PIIDoZZNmKGG{cnXzeEBidmRiYYDvdJRwe2m| MoLnNlM5OTZ6MU[=
HL-60 NH62bpRCeG:ydH;zbZMhSXO|YYm= NH3FZ4I2OML3TR?= NWjBNXdNPGh? M3v0SIJtd2OtczD0bIUh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|LDCtPUwh[W6mIGDBVnAhcW6mdXPl[EBjgSB4cx?= NIDDVHkzOzhyNEewOi=>
Ec-109 MnHqRZBweHSxc3nzJGF{e2G7 M3r2SlExKM7:TR?= MnrROFhp M1vrZ5JmeHKnc4Pld{BRTS2vZXTpZZRm\CCHYz2xNFkh[2WubDDhdI9xfG:|aYO= NVPyeId7OjN5OEK2OFE>
RKO NIjEe2RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHPjZoIyOCEQvF2= MWiyOIg> M13Q[4lvcGmkaYTzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSClYYXz[YQh[nliRFHC M2r5fVI{PzV6ME[0
T98G M1\URmNmdGxiVnnhZoltcXS7IFHzd4F6 MYixMVExOM7:TR?= NXriN|VWOjSq MoXvbY1xem:4ZYOgZ4VtdCC4aXHibYxqfHliY3;0doVifG2nboSge4l1cCCWUx?= NXLXbVRkOjN5NkmyO|U>
Jurkat NULxfHNkS2WubDDWbYFjcWyrdImgRZN{[Xl? NYi5bmZqOTByLUKwNO69VQ>? MUOyOIg> NV\s[mxNcW6qaXLpeJMhUGGDNDDpcoR2[2W|IHHwc5B1d3OrczDk[ZBmdmSnboSgc4Yh[2:wY3XueJJifGmxbtMg M1WyR|I{PzN{NEix
Molt-3  MVLBdI9xfG:|aYOgRZN{[Xl? NYfHXZBIPTEQvF2= NFu5bWszcA>? NYPMcYpEemWmdXPld{Bu\WyjdH;ubY4ucW6mdXPl[EBieG:ydH;zbZM> MVKyN|czPTBzMx?=
hMSC12 MX;BdI9xfG:|aYOgRZN{[Xl? NY\qdmpSOTByzszN M13aW|Rl NXftOIhOcW6qaXLpeJMhd3O2ZX;n[Y5q[yCldXz0eZJmNWmwZIXj[YQh[2WubDDk[YF1cCCjbnSgZ4Ft[2moaXPheIlwdg>? NUXYdFBpOjN4NUe4NlI>
HM7  NFLyfZFCeG:ydH;zbZMhSXO|YYm= MoXiNlDPxE4EoB?= NW\N[nhxOWh? NG[yO|hjdG:la4OgZZBq[3WuYYLlckBCKGGlZYTheIUucW6mdXPl[EBk[XOyYYPlMVMh[WO2aY\heIlwdiCjbnSgVGFTWCClbHXheoFo\Q>? M3i5SlI{PTh|NEGy
Hep-2  M{LvdmFxd3C2b4Ppd{BCe3OjeR?= M3XaVlIx|ryPwrC= M13mc|I1cA>? NE\1WplFVVOR MUfhcIxmfmmjdHXzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSCrbnT1Z4VlKGK7IIPpcIljcW6rbh?= NE\5O2gzOzV6MECzNi=>
HSCs MmO5RZBweHSxc3nzJGF{e2G7 MUm1NO69VQ>? M{j2c|I1cA>? NGP1O5RFVVOR Mn;sbY5pcWKrdIOgcoltd3SrbnniMYlv\HWlZXSgSG5CKGSjbXHn[UBqdmSrY3H0[YQh[nliUFHSVEBkdGWjdnHn[S=> MViyN|Q6QTh5NB?=
HL-60  Mo\iR5l1d3SxeHnjbZR6KEG|c3H5 NX;pbFAzOjEQvF5CpC=> NX7aR5FxOjSq NF\ST|Nz\WS3Y3XzJJRp\SCleYTveI95cWNiZX\m[YN1KG:oIFXyfVU> M13EOVI{PDl2NEiw
HA NVjvOm46SXCxcITvd4l{KEG|c3H5 M{jxTlUx|ryP MkPPNlRp NGK2T3p{fXCycnXzd4V{KHSqZTDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMtKC15LDDhcoQhNTliaX7keYNm\CCkeTDic5J1\XqxbXniM3NCUEF? NVKw[WU{OjN2N{W5OVY>
C666-1 M3L5RWFxd3C2b4Ppd{BCe3OjeR?= Ml\TOVDPxE1? MVWyOIg> M2TFRZN2eHC{ZYPz[ZMhfGinIHPs[YF3[WenIH;mJHBCWlBiYX7kJINie3Cjc3WtN{whNTduIHHu[EAuQSCrbnT1Z4VlKGK7IHLvdpRmgm:vaXKvV2FJSQ>? NV7UfGZvOjN2N{W5OVY>
Hepa1-6 Ml7lRZBweHSxc3nzJGF{e2G7 NF3jN4k2OM7:TR?= MlHPNog> MUDpcohq[mm2czDjeZJkfW2rbjDhcoQhemW|dnXyZZRzd2xvaX7keYNm\CCjcH;weI9{cXN? NXy1UG1OOjN2NE[3OVM>
PLC/PRF/5c MWTBdI9xfG:|aYOgRZN{[Xl? MkTqOVDPxE1? NUj0V3RiOWh? NGj0ZY5xemW4ZX70d{BieG:ydH;zbZMhfHKrZ3fldoVlKGK7IFPJUi=> M1fBb|I{PDN6OEK0
HCT116 Mo\ORZBweHSxc3nzJGF{e2G7 NVLBfopKOTByzszN NU\sZm13OS53aB?= NFn2SJlqdmirYnn0d{BQey2rbnT1Z4VlKGOnbHyg[IVifGh? NHzubpkzOzd2NEO1Ny=>
HCEC M{PMT2Z2dmO2aX;uJGF{e2G7 M4mwbVUx|ryP NEj5WlY4Omh? NEfWSFhFVVOR NX;jVm1KemW|dH;y[ZMhd2ZidHjlJI5wem2jbDDIR2VEKHCqZX7veJlx\Q>? NYTIc5VuOjN5NEKwNVE>
Primary rat cerebral cortical neurons NXXoS5FuSXCxcITvd4l{KEG|c3H5 MU[xNFDPxE1? MkLxNYg> M1nJcJBz\X[nboTzJGNlNWmwZIXj[YQh[XCxcITvd4l{KGGwZDDj[YxtKGSnYYTo NIXYc|QzOzd2MUOxOy=>
MDA-MB-231  NEjNblNCeG:ydH;zbZMhSXO|YYm= MVuyOe69VQ>? MX6yOIg> NEHxT5Ji[nKxZ3H0[ZMh[3m2b4TvfIlkcXS7IHHu[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiaX7keYNm\CCkeTDS[|M> NWPSUnhSOjV|M{e1OFQ>
NLRP3-Tet-on-MC/9  NHO4V5VCeG:ydH;zbZMhSXO|YYm= NXjNcllVOTBvNEFOwG0> NYP4dYtrOTKq NF[3SoFifHSnboXheIV{KHSqZTDj[YxtKGSnYYToJINifXOnZDDifUBESVCVLXHzd49kcWG2ZXSgUmxTWDNibYX0ZY51eyCrbjD0bIUhXGW2LX;uJJN6e3SnbR?= MlLiNlM4ODN|OEm=
KNS42  MX;BdI9xfG:|aYOgRZN{[Xl? MmfMOVDPxE1? NVHqbYp6OWh? NIq4TGFz\WS3Y3XzJINmdGxiZHXheIgh[W6mIHPvcZBt\XSnbImgZYJwdGm|aHXkJINie3Cjc3WgN{84KGGldHn2bZR6KGmwIILld5BwdnOnIITvJGFDXC1{NkOvNmRIN22ndH\vdo1qdiClb33ibY5ifGmxbh?= NVHVR5V{OjN4OUGxOFU>
MCF-7  NEfwTlBCeG:ydH;zbZMhSXO|YYm= M3fTXVIx|ryPwrC= NWTveHRoPzKq M1XLU4lvcGmkaYTzJIVyfW:uLTDhcoQhPC2RSGStcYVlcWG2ZXSgZZBweHSxc3nz MlfKNlM3PzV4NEO=
hCMEC/D3  NVjkeVN7SXCxcITvd4l{KEG|c3H5 NVvxNHA{OjYQvF2= NVvKfnk6PzKq MYny[YR2[2W|IFz0fGEhcW6mdXPl[EBieG:ydH;zbZM> NWn2co9mOjN4NkWxPVg>
Jurkat MnrHRZBweHSxc3nzJGF{e2G7 MVqxNk42NTVyzszN MWqxbC=> NIKzUpNld3OnIHTldIVv\GWwdHz5JJN2eHC{ZYPz[ZMhW1CKLXnu[JVk\WRiUHHyMVQh[2ynYY\h[4UtKFCDUmCgZ4xm[X[jZ3WsJGRPSSCocnHncYVvfGG2aX;uMEBidmRibH;zd{Bw\iC4aXHibYxqfHl? M1i0[FI{PDR{OUe2
CNE-1 M3vWVWFxd3C2b4Ppd{BCe3OjeR?= MXWyNO69VcLi NUnUeIRIOjSq NFvwOGtqdmirYnn0d{BTSURyMEGtbY5lfWOnZDDj[YxtKGSnYYTo NHLrVXQzOzR{Nki1NC=>
HONE-1 M4fBcmFxd3C2b4Ppd{BCe3OjeR?= MonPNlDPxE4EoB?= MlT4NlRp MV;pcohq[mm2czDSRWQxODFvaX7keYNm\CClZXzsJIRm[XSq M1zvN|I{PDJ4OEWw
astrocytes cell MlXXRZBweHSxc3nzJGF{e2G7 MW[0NO69VQ>? Mo\qOog> MlXTdoVlfWOnczDlZZJtgSCjcH;weI9{cXNiaX7keYNm\CCkeTDzeIF2em:|cH;ybY5m NYPxbmVPOjN2MUG3O|g>
U-937 NES2e2VCeG:ydH;zbZMhSXO|YYm= NWLBTFM6OTEQvF2= NGe1Tmc{OG2rbh?= NUP4bXdXeHKndnXueJMhXE6ILXnu[JVk\WRibnXjdo9xfG:|aYO= MoXQNlM1OTB5NEi=
MDA-MB-231 MX3BdI9xfG:|aYOgRZN{[Xl? MVqxNFDPxE1? MorMNYg> MWfpcohq[mm2czDz[Y5{cXSrenH0bY9vKHSxIGTSRWlNKHWyb36gUXRFUCCmb4fuMZJm\3WuYYTpc44> NEHFfWgzOzRyOESyPS=>
HeLa  NHOzbW9CeG:ydH;zbZMhSXO|YYm= NW\OUGcyOTByzszN M1HGVFJp NX;RUWJC[myxY3vzJGpTWy1zNTDJcoR2[2W|IFHwc5B1d3SrYzDD[YxtKESnYYTo MYCyN|M1PDB2NR?=
Ec109 M4j4eGFxd3C2b4Ppd{BCe3OjeR?= M3vi[VEx|ryP MVO2bC=> M1TQboJtd2OtczDhdI9xfG:2aXOgZ49u[mmwYYTpc44hd2ZiVHH0MXNu[WOQNzDhcoQhemGmaXH0bY9v MW[yN|M{QDV4OB?=
H460  M2K0[WFxd3C2b4Ppd{BCe3OjeR?= M4HLbVEx|ryP NWLjb4ltPmh? MmfWZoxw[2u|IHHwc5B1d3SrYzDjc41jcW6jdHnvckBw\iCWYYStV41i[055IHHu[EBz[WSrYYTpc44> M2DNdVI{OzN6NU[4
HeLa  NYXYSIlDSXCxcITvd4l{KEG|c3H5 M{nXeFUx|ryP M13HUVEvPWh? NX7sTGlQ[WK{b3fheIV{yqCFaHzhcZllcWFvaX7keYNm\CCjcH;weI9{cXN? NVXvOmg6OjN|MEO4NFQ>
SK-HEP1 MWTBdI9xfG:|aYOgRZN{[Xl? MkX1NVAx|ryP Ml;5NYg> M4izcolvcGmkaYTzJGNzXDFiYXP0bZZifGWmIHPhd5Bie2VvMzygMVctKC16LDCtPUwh[W6mIIDvcJkpSUSSLYLpZo9{\SlicH;sfY1memG|ZR?= MVGyN|MxOjZ3MB?=
QGY7701 Mme2RZBweHSxc3nzJGF{e2G7 MkXYNlXPxE1? MUWxMlVp MnLpbY5pcWKrdIOgZYNkfW23bHH0bY9vKG:oIIP1Zk1IOSCyaHHz[UBqdmS3Y3XkJIJ6KESRWDCrJJF2\XKlZYTpci=> MVOyN|I1ODB4MR?=
HepG2 MW\BdI9xfG:|aYOgRZN{[Xl? MXqyNO69VQ>? MnnyN|BucW5? NWTt[ZVXcW6qaXLpeJMhfGinIHXubIFv[2WmIHPlcIwh\GWjdHigZpkh[2:vYnnu[YQhfHKnYYTt[Y51KG:oIHHwbYdmdmmwIHHu[EBVWkGLTB?= NWO5U3RnOjN{MkSyN|k>
U87  MlT5RZBweHSxc3nzJGF{e2G7 NF\oeZEzPc7:TR?= NH3tc4QzcA>? NF\ONmll\WO{ZXHz[ZMhcXOxbHnxeYlzcXSrZ3XubY4hMEmVTDmtbY5lfWOnZDDhdI9xfG:2aXOgZ4VtdCCmZXH0bEwh[nW2IH7veEBv\WO{b4TpZ{Bk\WyuIHTlZZRp NIPOSYMzOzJ{OU[yOi=>
HSC-2 M4\PS2Fxd3C2b4Ppd{BCe3OjeR?= M3S0[|I2NzVyzszN NInERowycA>? MonqbY5pcWKrdIOgV24uOzhvaX7keYNm\CCleYTveI95cWOrdIm= M4myS|I{OTV3MkS4
HSC-4 MmXyRZBweHSxc3nzJGF{e2G7 Ml3BNlUwPTEQvF2= M2nwTlFp Mn3IbY5pcWKrdIOgV24uOzhvaX7keYNm\CCleYTveI95cWOrdIm= MYOyN|E2PTJ2OB?=
CL-1 NUTFWG1ZSXCxcITvd4l{KEG|c3H5 NF7QTGczOM7:TR?= Mm\wNYg> MVjicI9kc3NiT2C0OFkhcW6mdXPl[EBk\WyuIHTlZZRp NXvzOGRNOjNzM{G3PFI>
MEL NIj5UmJCeG:ydH;zbZMhSXO|YYm= NGHiXZUzOM7:TR?= NETpNYYzPGh? M4PzeWROW09? M4\lcIlueGGrcnXzJHAzYDdvaX7keYNm\CCPRVygZ4VtdCCjcH;weI9{cXN? MkHENlMxOTR6OEe=
Bel-7402  MYDDZZNx[XOnIFHjeIl3[XSrb36gRZN{[Xl? MVS1NO69VQ>? MVeybC=> MYTpcohq[mm2czDQR2UucW6mdXPl[EBidm:ra3nz Mn:xNlMxODh5NEK=
Eca-109 MWrBdI9xfG:|aYOgRZN{[Xl? NX3tNnpGOjYQvF2= MX[zNI1qdg>? NHjHPJZqdmirYnn0d{BDUi2EMUGtbY5lfWOnZDDj[YxtKGSnYYTo Mme4NlMxPzZ7Nke=
MEL NEPEb|dCeG:ydH;zbZMhSXO|YYm= M2DWOVIx|ryP NYLwRmRqOWh? MnTrSG1UVw>? NGTCdHlqdXCjaYLld{BROlh5LXnu[JVk\WRiTVXMJINmdGxiYYDvdJRwe2m| MXGyN|AyPDh6Nx?=
Bel-7402  M{PFfWFxd3C2b4Ppd{BCe3OjeR?= NUPGXZR6PTEQvF2= MYqybC=> NIjmSolqdmirYnn0d{BRS0VvaX7keYNm\CCjbn;pb4l{ M3HNOlI{ODB6N{Sy
L929 MWfGeY5kfGmxbjDBd5NigQ>? NXuwd2o3Oi53zszN NV:0PIFWOWh? MX\pcoNz\WG|ZYOgVmlROSCneIDy[ZN{cW:wIHHu[EBmgGGlZYLiZZRm\CCWTldOtU1qdmS3Y3XkJI1qfG:laH;u[JJq[WxiZInz[pVv[3Srb36gZY5lKFKRUzDwdo9lfWO2aX;u MlKyNlMxODB3MUi=
RCC  Mn;JR4VtdCCYaXHibYxqfHliQYPzZZk> MmLWNVAx|ryP NHLWdm4zPGh? M4XXSJJm[2:4ZYLld{B1cGVidnnhZoltcXS7IH;mJINmdGy|IHX4dI9{\WRidH:gNVVlNVCJSkK= NYj2TVdoOjJ7OUG0PVQ>
NB2a/d1 NXHtWGh[SXCxcITvd4l{KEG|c3H5 Mme2NVAx|ryP NHzEbmw4Omh? MW\heJRmdnWjdHXzJJN1[XW{b4Pwc5JqdmVvaX7keYNm\CClYYPwZZNmKGGldHn2bZR6NCCSQWLQMEBidmRidHH1JINt\WG4YXfl MXyyNlk5QDV2MR?=
T cell M1vSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jHfVI2NTFyMN88US=> MonWNlRp MUnkc5NmNWSncHXu[IVvfGy7IHnubIljcXSnZDDUJINmdGxicILvcIln\XKjdHnvckBu\WSrYYTl[EB1cHKxdXfoJJRp\SClbz3zeIlufWyjdHnvckB4cXSqIHHueIkuS0R|IHHu[EBidnSrLVPENlg> Ml21NlI6QDJ3M{i=
K562 MnjiRZBweHSxc3nzJGF{e2G7 MXKxNFDPxE1? M3;XdlFp MlPjZoxw[2u|IFHico9j[X[rc3P1ceKhTi2rbnT1Z4VlKGGyb4D0c5Nqew>? MnjoNlI6PzJ|N{K=
Jurkat  MVXBdI9xfG:|aYOgRZN{[Xl? NIHKOYo1OM7:TR?= M3XENlFp NGDGbHFi[m:uaYPo[ZMhTmG|TD3pcoR2[2WmIHPhd5Bie2ViYXP0bZZifGmxbjDhcoQh[2WubDDk[YF1cA>? Mm\6NlI6PDJ5M{i=
BGC-823 MoD4RZBweHSxc3nzJGF{e2G7 NHjRSVMyODEQvF2= NVnCZZRIOWh? MWPwZZJ1cWGubImgdoV{[3WnczDj[YxteyCjZ3HpcpN1KGSjbXHn[UBw\iCmYXnkfoVqdg>? MkDGNlI6OjZ3NEW=
Hep3B MmDFRZBweHSxc3nzJGF{e2G7 NUH6Uo54PTEQvF2= NXzTO45XOWh? M4H2NIJtd2OtczDhdI9xfG:|aYOgbY5lfWOnZDDifUBJTUeFcx?= MVWyNlkzOzF3NB?=
LLC-PK1 M1nVWGFxd3C2b4Ppd{BCe3OjeR?= NE\x[IUzOM7:TR?= M2LoWlFp M4jFUpBz\X[nboTzJINqe3CuYYTpck1qdmS3Y3XkJIRm\3KjZHH0bY9vKG:oIFH0[|UtKGKnY3zpck0yNCCjbnSgRZRoOTJicILveIVqdnN? MWKyNlg6PjB|Nx?=
A549 MmTIRZBweHSxc3nzJGF{e2G7 NEDRXnk2OM7:TR?= MYmxbC=> NF74WlhjdG:la4OgeIhmKEKDST3pcoR2[2WmIHHwc5B1d3Orc9Mg NGG3TWszOjh6N{KxOS=>
SGC-7901  NILJenpCeG:ydH;zbZMhSXO|YYm= MVixNO69VQ>? MVqyOIg> NI\UNVFqdmirYnn0d{DPui{Qsj3kbY1mfGi7bHHjdplte2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZPDqA>? NE\Xb3MzOjh2OEW5Oy=>
DM6 M2\Lb2Fxd3C2b4Ppd{BCe3OjeR?= NWLKRmdMOTByzszN M3G4e|czcA>? NWmyTnJV[myxY3vzJIJwfGhiRULGMVEh[W6mIFWySpRzNW2nZHnheIVlKGO7dH;0c5hq[2m2eR?= MYGyNlgzPTN{OB?=
MCF-7, MDA-MB-468, Caco-2 M{XjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWW1NO69VQ>? NH6wWpU1QGh? NF30eJVqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KHOjcH;ubY4> MlTGNlI5ODB7Nki=
A2750  MXLBdI9xfG:|aYOgRZN{[Xl? M4n6OFIx|ryP MV:ybC=> NIWy[2JFVVOR NX3nfHNH[myxY3vzJINie3Cjc3WgZ4xm[X[jZ3Wg[JVzcW6pIHjlcIVv[WyrbjD0doVifG2nboSgZY5lKHKnZIXj[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq MWeyNlc5PDN4Mx?=
U87  NVvXe4F5SXCxcITvd4l{KEG|c3H5 Mke2NlDPxE1? NF\DOXczPGh? MljLdoVlfWOnczD0bIUh[XCxcITvd4l{KHKjdHWgbY5lfWOnZDDifUBRVEGE MXmyNlc4QDd6MB?=
HT1080 NYTmZodIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLKOVDPxE1? MU[3[C=> M17yTolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpcohq[mm2aX;uJINifXOnZDDifUBkd22kaX7l[EB1emWjdH3lcpQhd2ZiRFPBJIFv\CCRTWC= MYGyNlc1ODl6NB?=
A549  NYjvU3pvSXCxcITvd4l{KEG|c3H5 NYHwPItZPTEQvF2= MXiybC=> MV;wZZJ1cWGubImg[IVkemWjc3XzJJNw\Gm3bTDz[Yxmdmm2ZT3pcoR2[2WmIHHwc5B1d3Orcx?= MljINlI4OjF6MES=
Primary OPC MmrDRZBweHSxc3nzJGF{e2G7 MYex{txO MYO2bE8zPGh? NHHhcpBz\WS3Y3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGy|IHnuJIViemy7LTDhcoQhdGG2ZT3hdI9xfG:|aYOvcoVkem:|aYO= M{K0[lIzPzB5M{i1
PMNs NHLpZ3dCeG:ydH;zbZMhSXO|YYm= MYq0NO69VQ>? NGL1fFg3cA>? MVfEUXNQ NXrMSGpYemW4ZYLz[YQhfGinIHHtc5VvfCCxZjDjcIVifmWmIHPhd5Bie2VvMzD0c{Bv\WG{II\lbIlkdGVibHX2[Yx{ M2jlSVIzPjl{NUe3
A549  NVfQVYlRSXCxcITvd4l{KEG|c3H5 NGjpXJQ2OM7:TR?= M3vVcVFp NXHiVlhWeHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliQnHvbJVwe2mmZTDJ NYS0eGZzOjJ4OEe2N|U>
AGS M{XNfmFxd3C2b4Ppd{BCe3OjeR?= NUOy[Xl5OjEQvF2= NVPNUWZkOTKq MUDpcohq[mm2czD0bIUh[WO2aY\heIlwdiCxZjDwdo8u[2G|cHHz[U0{KGmwIILld5BwdnOnIITvJJRp\SCHdF;BZ{BnemGldHnvci=> NEPYO44zOjZ6N{O5PC=>
shC9  MmDzRZBweHSxc3nzJGF{e2G7 MXmxNO69VQ>? M{\1flE3cA>? MYjicJVvfHNiU1jIJIV5eHKnc4Ppc44hcW5ic3jDPUBk\WyuczDlfJBwe2WmIITvJIVqfGincjDQRUBweiCOUFO= NYTqb2w4OjJ4NEGwPVQ>
primary MEFs MmTaSpVv[3Srb36gRZN{[Xl? MoPsNVJp Mnj2xsBqdmO{ZXHz[ZMh\XSxcH;zbYRmNWmwZIXj[YQhdWm2b3Poc45lemmjbDDt[Y1jemGwZTDk[ZBwdGG{aYrheIlwdg>? MoW2NlI3OTN5Nke=
3T9 MEFs NFnyZWhHfW6ldHnvckBCe3OjeR?= NY[5dY1tOT[q MofVbY5kemWjc3XzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGGodHXyJIV1d3Cxc3nk[U11emWjdH3lcpQ> M3vtN|IzPjF|N{[3
3T9 MEFs MV\GeY5kfGmxbjDBd5NigQ>? MmWzNVhp M4HBNZVxemWpdXzheIV{KGmwaYTpZZRweiClYYPwZZNmNTliYoX0JIRwf26{ZXf1cIF1\XNiZX\m[YN1d3JiY3HzdIF{\XNiYX\0[ZIh\XSxcH;zbYRmKHS{ZXH0cYVvfA>? NEXqSnMzOjZzM{e2Oy=>
MDA-MB-231  M37HbmFxd3C2b4Ppd{BCe3OjeR?= MVuyNO69VQ>? M4\1clRl NFvHfHhz\WS3Y3XzJJRp\SClZXzsJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KG2ndH\vdo1qdiC2cnXheI1mdnRid3HzJJNq\26rZnnjZY51dHl? Mkf4NlI2QTN2NEG=
C6  MlT4RZBweHSxc3nzJGF{e2G7 MUCxNO69VQ>? MnP6NlRp M3f3fIJtd2OtczD0bIUhe3WycILld5NqfmViZX\m[YN1KG:oIITo[UBx\XC2aXTlJI9vKH[rYXLpcIl1gQ>? NUXPVppkOjJ3OEi5PFA>
HL-60  Mo\nRZBweHSxc3nzJGF{e2G7 NIO0c5oyODEQvF2= M17IVVI1cA>? MX3pcohq[mm2czD0bIUh[2WubDDhdI9xfG:|aYOgd4Vt\WO2ZXSgLEsqNW2nboTofYwh|rJvKEJiirI3MS2maXfseYNweHm{YX7vd4ll\cLiNR?= NH;CSHQzOjV2Nk[2PS=>
HL-60 MmjSRZBweHSxc3nzJGF{e2G7 NH3aS|kyOC16MN88US=> NHHLd2s1cA>? NUTndHZwcW6qaXLpeJMhXEeKUT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{yqB? MXiyNlUzOzJ{OR?=
BCC M2XpRWFxd3C2b4Ppd{BCe3OjeR?= M1GzSVUx|ryP MYKxbC=> NUPyTGU{cW6qaXLpeJMhTEGWUz3t[YRq[XSnZDDndo94fGhiaX7obYJqfGmxbh?= M{fjXFIzPTF7NEO2
RAW 264.7 NWrsVZVLSXCxcITvd4l{KEG|c3H5 NFLpZpE2OC9zMEFOwG0> MX6xbC=> NXO2UW1K[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5pcWKrdIOgSG9PNWmwZIXj[YQhelKQQTDjcIVifmGpZR?= NUfBXHdOOjJ2OUG0NlY>
K562 NXL1[odTSXCxcITvd4l{KEG|c3H5 NHvIeokzPc7:TR?= MY[ybC=> NUfObXR2eHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3:teJJm[XSvZX70JJdqfGhiYX31doVve2mwIFegZY5lKFSUQVnM NXfxc49vOjJ2OEO3O|c>
SGC-7901 MUXBdI9xfG:|aYOgRZN{[Xl? NYTC[mhEOjBizszNxsA> MmD5Nog> MnK0ZZR1\W63YYTld{BJOk9{wrDvdkBVVkZizsGtbY5lfWOnZDDj[YxtKGGyb4D0c5NqeyCjczD3[YxtKGG|IHPhd5Bie2VvMzDhZ5Rqfmm2edMg NV;hSmd4OjJ2N{G1PFk>
PC3 NUOxb|c4SXCxcITvd4l{KEG|c3H5 NVzQUW1[OTEQvF2= MoLpOIg> M4XrUoNwfW62ZYLzJIZt[X[xY3;4bYQucW6mdXPl[EBk[XOyYYPlMZJmdGG2ZXSgZZBweHSxc3nz MX:yNlQ4OTl5NB?=
SMMC-7721 MWrBdI9xfG:|aYOgRZN{[Xl? MmPUOVDPxE1? MmXkOFhp Mm\mZZR1\W63YYTld{BwXFJvaX7keYNm\CCjcH;weI9{cXN? NXrWdJN6OjJ2NkW4N|M>
HeLa  MkLxRZBweHSxc3nzJGF{e2G7 MUG1NOKh|ryP NH3GblA1Nziq M33idYlvcGmkaYTzJHNVWy2rbnT1Z4VlKGyjdHWtdIhie2ViYYDvdJRwfGmlIHX2[Y51ew>? NIrJTJQzOjR4MEWwOC=>
HeLa  NX\I[lhmSXCxcITvd4l{KEG|c3H5 M1fVNFUxyqEQvF2= NGDQdowycA>? MUnzeZBxemW|c3XzJJRp\SCIUlHQMYlv\HWlZXSgZYNkfW23bHH0bY9vKG:oIHHucoV5cW5iVjDwc5NqfGm4ZTDj[Yxtew>? M4XnS|IzPDR7NESw
T47D  M4HnSWFxd3C2b4Ppd{BCe3OjeR?= MXexNFDPxE1? NWLpR25iOWh? MmjCZoxw[2u|IITo[UBo\W6ncnH0bY9vKG:oIFWtZ4FlN0OWRkKgZpkhW1SV Moq0NlI1ODFzNki=
HeLa  M37WUmFxd3C2b4Ppd{BCe3OjeR?= MnPHN|DPxE1? NYPZW|d2PGh? MoDjxsBqdmO{ZXHz[ZMhfGinIHflcoVz[WxiY3XscEB3cWGkaXzpeJkhPDhiaDDh[pRmeiCyaH;0c4R6dmGvaXOgeJJm[XSvZX70xsA> MlKzNlI{QTR{NEi=
HCC NEC4S5RCeG:ydH;zbZMhSXO|YYm= NWLqT3pLOjBizszNxsA> NFO5NWkzcA>? NIXSWGZifHSnboXheIV{KHSqZTDETGEhcW6mdXPl[EBi[3SrdnH0bY9vKG:oIGDBVnA> NG\BcnczOjN2MkezNi=>
mESCs NEKwNWRCeG:ydH;zbZMhSXO|YYm= MYSyMlXPxE1? NX3zepBlOmh? MmD0bY5pcWKrdIOgeIhmKE6jRj3t[YRq[XSnZDDjZZNx[XOnIHHjeIl3[XSrb36= NIXvWIIzOjJ6NUK3OC=>
EMT-6  MYXDfZRwfG:6aXPpeJkhSXO|YYm= NFHqfo8yODEQvF2= MoTNNYg> Moi4dIFzfGmjbHz5JIJtd2OtZXSgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KHOrcnHt[ZNqdmV? NH\Cc44zOjJ3MUmyNS=>
MCF7 NGH4NWdCeG:ydH;zbZMhSXO|YYm= MVe1NOKh|ryP MV:xbC=> Mmq3bY5pcWKrdIOgVGEh[WO2aY\heIVlKGOjc4Dhd4UuOyxiLUmsJIFv\CCyb3z5LGFFWC2{aXLvd4UqKHCxbInt[ZJie2V? MVeyNlIzOzN2NR?=
K562 Mmn2RZBweHSxc3nzJGF{e2G7 M3zJUVIxKM7:TdMg MkDEOFhp Mn7USG1UVw>? M1rZcIJtd2OtczDsZZBifGmwaXKtbY5lfWOnZDDpcohq[mm2aX;uJI9nKH[rYXLpcIl1gSCjbnSgZZBweHSxc3nzJIlv\HWldHnvci=> MkTTNlIzOTZzNUi=
Molt4-hyg M1nScGFxd3C2b4Ppd{BCe3OjeR?= NELWNnMyOM7:TR?= NWjBOphtOC53aB?= Ml71Zoxw[2u|IH\hdo5me2:uLXnu[JVk\WRiY3HzdIF{\S1|LXzpb4Uh[WO2aY\peJk> NITnWGMzPjJ5NUixNS=>
HeLa NF[3N|ZCeG:ydH;zbZMhSXO|YYm= NV3nU3F[OTEQvF2= MojPNE42cA>? M3zERolvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KHSqZTDjc41jcW6nZDD0doVifG2nboSge4l1cCCpb33pd4lvKE5iYX7kJHRTSUmO NUfkNFVwOjJzN{m2OlE>
Jurkat T Mn7tRZBweHSxc3nzJGF{e2G7 NHrjdVk{OM7:TR?= NF;3TYUxNjWq NHXuN4lFVVOR NGXoRlJjdG:la4OgeIhmKHqrcnHtMYlv\HWlZXSgZZBweHSxc3nz NF\vZogzOjF3OUi5PC=>
Neutrophil MoPqRZBweHSxc3nzJGF{e2G7 MYGyNO69VQ>? M4e4[VAvPWh? M{XV[oF1fGWwdXH0[ZMhfGinIIDyc{1ieG:ydH;0bYMh\W[oZXP0JI9nKE2jUkG= M1jaS|I3OTl4OES0
HCT116 NGnWUplCeG:ydH;zbZMhSXO|YYm= M3ewcVUxyqEQvF2= NH3wN2ozcA>? MWPy[ZZmenOnczDzfY5memerc4TpZ{BieG:ydH;zbZMh\W[oZXP0d{Bw\iClZXzlZ495cWJiYX7kJG5RSy1zNtMg NIXMbHczOjF3OUe1Ni=>
MDA-MB-231  NXTa[mdrSXCxcITvd4l{KEG|c3H5 M4rKNFIvPS15LkZOwG0> Mn34Nog> Mlu3bY5pcWKrdIOgeIhmKGOnbHyg[IVifGhib3[gUWRCNU2ELUKzNUBk\WyuczDpcoR2[2WmIHL5JHNFXCCrbjDhJINwdmOnboTyZZRqd25iZHXw[Y5l\W62IH3hco5meg>? MXiyNlEyPTV{Nh?=
LNCaP M4DjXmFxd3C2b4Ppd{BCe3OjeR?= MUG0NO69VQ>? NF3sR4QzcA>? M{\TWolvcGmkaYTzJIJ2fGWrbjDpcoR2[2WmIHPlcIwh[XCxcITvd4l{ MY[yNlEyPDd4NB?=
MB231 NUHKdI9[SXCxcITvd4l{KEG|c3H5 NETHbWoyODEQvF2= NF\TRXgycA>? NVzZcWV2TE2VTx?= MkHYZYJzd2ejdHXzJJRp\SCrbnT1Z5Rqd25ib3[gZ4VtdCCmZXH0bEBjgSCZRVWxJIlvcGmkaYTpc44tKFSUQVnMJJRz\WG2bXXueEwh[W6mIITo[UBkd22kaX7heIlwdg>? NXPQUZpzOjJzMUK5OFA>
HCC38  NU\CV4VkSXCxcITvd4l{KEG|c3H5 M3LkOlExOM7:TR?= Mk[yNYg> M1PqeGROW09? M2jXWoFjem:pYYTld{B1cGViaX7keYN1cW:wIH;mJINmdGxiZHXheIgh[nliV1XFNUBqdmirYnn0bY9vNCCWUlHJUEB1emWjdH3lcpQtKGGwZDD0bIUh[2:vYnnuZZRqd25? MUGyNlEyOjl2MB?=
MDA-MB231 NVLoXHN7SXCxcITvd4l{KEG|c3H5 M{K1NFUxyqEQvF2= NHj6[2czPGh? M33EPWROW09? M3vSVYFjem:pYYTld{BkfXKldX3pck1qdmS3Y3XkJINmdGxiZHXheIg> M4HSTFIzOTBzM{O1
LNCaP M3LORWFxd3C2b4Ppd{BCe3OjeR?= MW[1NOKh|ryP NWi0UlRCOjSq MkXOSG1UVw>? Mn7OZYJzd2ejdHXzJIN2emO3bXnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NXXDUGdEOjJzMEGzN|U>
HCT116 NXXPNG8{SXCxcITvd4l{KEG|c3H5 MVu1NOKh|ryP MXOyOIg> MXHEUXNQ NUe0RXBD[WK{b3fheIV{KGO3cnP1cYlvNWmwZIXj[YQh[2WubDDk[YF1cA>? Mni0NlIyODF|M{W=
Ishikawa  Mn3BRZBweHSxc3nzJGF{e2G7 Mnq2NlXPxE1? NFK4TnozPGh? NGi0dpFz\WS3Y3XzJINmdGxiZHXheIgh[W6mIHHwc5B1d3OrczDpcoR2[2WmIHL5JGJi\iCDMR?= MVmyNlA5QDlzOB?=
 YD-8  MVrBdI9xfG:|aYOgRZN{[Xl? M{e3WlExOM7:TR?= MoTlNYg> M{jN[4lvcGmkaYTzJHBNTU9vaX7keYNm\CCjcH;weI9{cXN? MX6yNlA5PjF6Mx?=
eosinophil  MXjBdI9xfG:|aYOgRZN{[Xl? NWfldIw2QTEQvF2= MYiyOIg> NImxNpRqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCIYYOgZY51cWKxZIpCpC=> M1WwdFIzODd7M{O0
L929 NHKyTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\HNk42|ryP MWWyOIg> MX;pcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDwMZA{QCCjbnSgUmYu|rqEIITvJIF2\22nboSgWG5H|rFvaX7keYNm\CCwZXPyc5B1d3OrczDhcoQh[XW2b4DoZYd6 MX6yNlAzPzB7Nx?=
YD-8  MnHqRZBweHSxc3nzJGF{e2G7 M3zTPVExOM7:TR?= MkXTNYg> NWjGS4ZU[myxY3vzJJRp\SCJUz3IR4wucW6mdXPl[EBieG:ydH;zbZM> MW[yNlAzODB5OB?=
HBx M2THemFxd3C2b4Ppd{BCe3OjeR?= NF\GUVQzPc7:TR?= MYC0PIg> Mn60SG1UVw>? NGnzUHdz\WS3Y3XkJINmdGxiZHXheIghcW6mdXPl[EBjgSB|LV3B M375N|IzODJyMEe4
U937  NYDzbJRPSXCxcITvd4l{KEG|c3H5 M3vablUxyqEQvF2= MU[xbC=> NFvxbpRqdmirYnn0d{BJTi2rbnT1Z4VlKGGyb4D0c5Nqe8Li Mn3mNlE6QTh5M{G=
HL60 M2LXO2Fxd3C2b4Ppd{BCe3OjeR?= NVvwc5JyPDEQvF2= M4e3UFQxdWmw M1u3N2ROW09? MX3icI9kc3NiQl7ER{Bkd22yb4Xu[JMhcW6mdXPlJIV5eG:|dYLlJI9nKHCqb4PwbIF1cWS7bIPldolv\SCjbnSgSG5CKG[{YXft[Y51[XSrb36= NWfEdFBVOjF7OEOyPVY>
M-14 NHfNPWxCeG:ydH;zbZMhSXO|YYm= M2LTWVI2|ryP MoP5NE42cA>? NVXhWYdIyqCrbnjpZol1eyCkb4ToJJRp\SClcoXk[UBmgHS{YXP0MUBidmRiY3;tdI92dmRvaX7keYNm\CCjcH;weI9{cXN? NInmXJYzOTl3NEm1PS=>
SK-BR-3 MmTzRZBweHSxc3nzJGF{e2G7 M3:xWFUxyqEQvF2= NIHPOngzcA>? NFf0NY1jdG:la4OgZZBweHSxdHnjJGRPSSCocnHncYVvfGG2aX;uJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25ib3[gV20uOTZ2IHHu[EBz[WSrYYTpc44> M{LRbFIyQTBzM{i2
MDA-MB-468 MkHSRZBweHSxc3nzJGF{e2G7 NET2bI82OMLizszN NVX2TWRiOmh? NYrtbnRO[myxY3vzJIFxd3C2b4TpZ{BFVkFiZoLh[41mdnSjdHnvckBqdmS3Y3XkJIJ6KGOxbXLpcoF1cW:wIH;mJHNONTF4NDDhcoQhemGmaXH0bY9v NF7LfZczOTlyMUO4Oi=>

... Click to View More Cell Line Experimental Data

In vivo In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

Protocol

Cell Research:

[6]

+ Expand
  • Cell lines: human granulosa cell lines (GC1a, HGL5, COV434)
  • Concentrations: 50 μM
  • Incubation Time: 48 h
  • Method:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD1 mice
  • Formulation: dissolved in DMSO, diluted in PBS (final concentration of DMSO < 1%)
  • Dosages: 10 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (198.93 mM)
Water Insoluble
Ethanol Insoluble warmed
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+35 %PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • Answer:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • Question 2:

    What is difference between S7023 & S8102?

  • Answer:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspase Signaling Pathway Map

Related Caspase Products0

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID